BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

695 related articles for article (PubMed ID: 23466078)

  • 1. Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: cardiac magnetic resonance substudy of the AIDA STEMI trial.
    Eitel I; Wöhrle J; Suenkel H; Meissner J; Kerber S; Lauer B; Pauschinger M; Birkemeyer R; Axthelm C; Zimmermann R; Neuhaus P; Brosteanu O; de Waha S; Desch S; Gutberlet M; Schuler G; Thiele H
    J Am Coll Cardiol; 2013 Apr; 61(13):1447-54. PubMed ID: 23466078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial.
    Thiele H; Schindler K; Friedenberger J; Eitel I; Fürnau G; Grebe E; Erbs S; Linke A; Möbius-Winkler S; Kivelitz D; Schuler G
    Circulation; 2008 Jul; 118(1):49-57. PubMed ID: 18559698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention: design and rationale of the Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) trial.
    Thiele H; Wöhrle J; Neuhaus P; Brosteanu O; Sick P; Prondzinsky R; Birkemeyer R; Wiemer M; Kerber S; Schuehlen H; Kleinertz K; Axthelm C; Zimmermann R; Rittger H; Braun-Dullaeus RC; Lauer B; Burckhardt W; Ferrari M; Bergmann MW; Hambrecht R; Schuler G;
    Am Heart J; 2010 Apr; 159(4):547-54. PubMed ID: 20362711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.
    Gu YL; Kampinga MA; Wieringa WG; Fokkema ML; Nijsten MW; Hillege HL; van den Heuvel AF; Tan ES; Pundziute G; van der Werf R; Hoseyni Guyomi S; van der Horst IC; Zijlstra F; de Smet BJ
    Circulation; 2010 Dec; 122(25):2709-17. PubMed ID: 21098442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between myocardial reperfusion, infarct size, and mortality: the INFUSE-AMI (Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction) trial.
    Brener SJ; Maehara A; Dizon JM; Fahy M; Witzenbichler B; Parise H; El-Omar M; Dambrink JH; Mehran R; Oldroyd K; Gibson CM; Stone GW
    JACC Cardiovasc Interv; 2013 Jul; 6(7):718-24. PubMed ID: 23866184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial.
    Thiele H; Wöhrle J; Hambrecht R; Rittger H; Birkemeyer R; Lauer B; Neuhaus P; Brosteanu O; Sick P; Wiemer M; Kerber S; Kleinertz K; Eitel I; Desch S; Schuler G
    Lancet; 2012 Mar; 379(9819):923-931. PubMed ID: 22357109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracoronary versus intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: 6-month effects on infarct size and left ventricular function. The randomised Leipzig Immediate PercutaneouS Coronary Intervention Abciximab i.v. versus i.c. in ST-Elevation Myocardial Infarction Trial (LIPSIAbciximab-STEMI).
    Eitel I; Friedenberger J; Fuernau G; Dumjahn A; Desch S; Schuler G; Thiele H
    Clin Res Cardiol; 2011 May; 100(5):425-32. PubMed ID: 21125288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aborted myocardial infarction in intracoronary compared with standard intravenous abciximab administration in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction.
    Eitel I; Desch S; Schindler K; Fuernau G; Schuler G; Thiele H
    Int J Cardiol; 2011 Nov; 153(1):21-5. PubMed ID: 20817283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracoronary compared to intravenous Abciximab and high-dose bolus compared to standard dose in patients with ST-segment elevation myocardial infarction undergoing transradial primary percutaneous coronary intervention: a two-by-two factorial placebo-controlled randomized study.
    Bertrand OF; Rodés-Cabau J; Larose E; Rinfret S; Gaudreault V; Proulx G; Barbeau G; Déry JP; Gleeton O; Manh-Nguyen C; Noël B; Roy L; Costerousse O; De Larochellière R;
    Am J Cardiol; 2010 Jun; 105(11):1520-7. PubMed ID: 20494655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-ambulance abciximab administration in STEMI patients prior to primary PCI is associated with smaller infarct size, improved LV function and lower incidence of heart failure: results from the Leiden MISSION! acute myocardial infarction treatment optimization program.
    Hassan AK; Liem SS; van der Kley F; Bergheanu SC; Wolterbeek R; Bosch J; Bootsma M; Zeppenfeld K; van der Laarse A; Atsma DE; Jukema JW; Schalij MJ
    Catheter Cardiovasc Interv; 2009 Aug; 74(2):335-43. PubMed ID: 19642182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infarct size and mortality in patients with proximal versus mid left anterior descending artery occlusion: the Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction (INFUSE-AMI) trial.
    Brener SJ; Witzenbichler B; Maehara A; Dizon J; Fahy M; El-Omar M; Dambrink JH; Genereux P; Mehran R; Oldroyd K; Parise H; Gibson CM; Stone GW
    Am Heart J; 2013 Jul; 166(1):64-70. PubMed ID: 23816023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention.
    Bellandi F; Maioli M; Gallopin M; Toso A; Dabizzi RP
    Catheter Cardiovasc Interv; 2004 Jun; 62(2):186-92. PubMed ID: 15170708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracoronary compared to intravenous abciximab in patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention reduces mortality, target vessel revascularization and reinfarction after 1 year.
    Iversen AZ; Galatius S; Abildgaard U; Galloe A; Hansen PR; Pedersen S; Engstroem T; Jensen JS
    Cardiology; 2011; 120(1):43-9. PubMed ID: 22122887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial.
    Stone GW; Maehara A; Witzenbichler B; Godlewski J; Parise H; Dambrink JH; Ochala A; Carlton TW; Cristea E; Wolff SD; Brener SJ; Chowdhary S; El-Omar M; Neunteufl T; Metzger DC; Karwoski T; Dizon JM; Mehran R; Gibson CM;
    JAMA; 2012 May; 307(17):1817-26. PubMed ID: 22447888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antecedent hypertension and myocardial injury in patients with reperfused ST-elevation myocardial infarction.
    Reinstadler SJ; Stiermaier T; Eitel C; Saad M; Metzler B; de Waha S; Fuernau G; Desch S; Thiele H; Eitel I
    J Cardiovasc Magn Reson; 2016 Nov; 18(1):80. PubMed ID: 27832796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracoronary versus intravenous bolus abciximab administration in patients undergoing primary percutaneous coronary intervention with acute ST-elevation myocardial infarction: a pooled analysis of individual patient data from five randomised controlled trials.
    Piccolo R; Eitel I; Iversen AZ; Gu YL; Dominguez-Rodriguez A; de Smet BJ; Mahmoud KD; Abreu-Gonzalez P; Thiele H; Piscione F
    EuroIntervention; 2014 Jan; 9(9):1110-20. PubMed ID: 24457282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Pericardial Effusion Complicating ST-Elevation Myocardial Infarction as Predictor of Extensive Myocardial Damage and Prognosis.
    Jobs A; Eitel C; Pöss J; Desch S; Thiele H; Eitel I
    Am J Cardiol; 2015 Oct; 116(7):1010-6. PubMed ID: 26235929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty.
    Wöhrle J; Grebe OC; Nusser T; Al-Khayer E; Schaible S; Kochs M; Hombach V; Höher M
    Circulation; 2003 Apr; 107(14):1840-3. PubMed ID: 12682003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis of prospective randomized controlled trials comparing intracoronary versus intravenous abciximab in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Shimada YJ; Nakra NC; Fox JT; Kanei Y
    Am J Cardiol; 2012 Mar; 109(5):624-8. PubMed ID: 22152971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1-Year Outcomes With Intracoronary Abciximab in Diabetic Patients Undergoing Primary Percutaneous Coronary Intervention.
    Piccolo R; Eitel I; Galasso G; Dominguez-Rodriguez A; Iversen AZ; Abreu-Gonzalez P; Windecker S; Thiele H; Piscione F
    J Am Coll Cardiol; 2016 Aug; 68(7):727-38. PubMed ID: 27515333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.